Fricker-Hidalgo Hélène, Bulabois Claude-Eric, Brenier-Pinchart Marie-Pierre, Hamidfar Rebecca, Garban Frédéric, Brion Jean-Paul, Timsit Jean-François, Cahn Jean-Yves, Pelloux Hervé
Parasitologie-Mycologie, Pôle Biologie, Centre Hospitalier Universitaire, Grenoble, France.
Clin Infect Dis. 2009 Jan 15;48(2):e9-e15. doi: 10.1086/595709.
The biological diagnosis of toxoplasmosis after allogeneic hematopoietic stem cell transplantation (HSCT) is based on the detection of Toxoplasma gondii DNA in blood specimens or other samples. Serological testing is used mainly to define the immunity status of the patient before HSCT. The aim of our study was to examine the performance of polymerase chain reaction (PCR) and serological techniques in the diagnosis of toxoplasmosis after HSCT.
Seventy patients underwent allogeneic HSCT from September 2004 through September 2006. DNA was detected by PCR, and immunoglobulin G and immunoglobulin M were detected by enzyme-linked immunosorbent assay.
The results of immunoglobulin G detection before allogeneic HSCT were positive in 40 (57.1%) of the patients and negative in 30 (42.9%). After HSCT, 57 patients (81.4%) had test results that were negative for immunoglobulin M and had negative results of DNA detection, without toxoplasmosis infection. Four patients (5.7%) had at least 4 samples with positive PCR results and/or test results positive for immunoglobulin M against T. gondii; toxoplasmosis was then confirmed by clinical symptoms. Nine patients (12.9%) with positive PCR results and 1 or 2 samples with test results negative for immunoglobulin M were considered to have asymptomatic T. gondii infection. Reactivation of latent infection was the cause of toxoplasmosis in 3 of the 4 patients, and toxoplasmosis occurred as a primary infection in 1 patient. The detection of specific anti-T. gondii immunoglobulin M was the only biological evidence of toxoplasmosis in 2 patients, and samples were positive for immunoglobulin M before PCR was performed in 1 patient.
Thus, after HSCT, all patients were at risk for toxoplasmosis; all patients who receive HSCTs should be followed up with biological testing that combines PCR and serological techniques.
异基因造血干细胞移植(HSCT)后弓形虫病的生物学诊断基于血液标本或其他样本中弓形虫DNA的检测。血清学检测主要用于确定患者在HSCT前的免疫状态。我们研究的目的是检测聚合酶链反应(PCR)和血清学技术在HSCT后弓形虫病诊断中的性能。
2004年9月至2006年9月期间,70例患者接受了异基因HSCT。通过PCR检测DNA,通过酶联免疫吸附测定检测免疫球蛋白G和免疫球蛋白M。
异基因HSCT前免疫球蛋白G检测结果为阳性的患者有40例(57.1%),阴性的有30例(42.9%)。HSCT后,57例患者(81.4%)免疫球蛋白M检测结果为阴性且DNA检测结果为阴性,无弓形虫感染。4例患者(5.7%)至少有4份样本PCR结果为阳性和/或抗弓形虫免疫球蛋白M检测结果为阳性;随后根据临床症状确诊为弓形虫病。9例PCR结果为阳性且1或2份样本免疫球蛋白M检测结果为阴性的患者被认为有无症状弓形虫感染。4例患者中有3例弓形虫病是由潜伏感染的激活引起的,1例患者弓形虫病为原发性感染。2例患者中,特异性抗弓形虫免疫球蛋白M的检测是弓形虫病的唯一生物学证据,1例患者在进行PCR检测前样本免疫球蛋白M呈阳性。
因此,HSCT后所有患者都有患弓形虫病的风险;所有接受HSCT的患者都应采用结合PCR和血清学技术的生物学检测进行随访。